Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491096 | 0.88 | HIF1A (0.46) | MAPK1TSHRACHEHIF1AMAPT | |
| SCHEMBL10665110 | 0.86 | ADRA1A (0.54) | ADRA1AADRA2ACYP2D6MAPK1ADRB2 | |
| SCHEMBL4981399 | 0.86 | CYP2D6 (0.58) | ADRA1AADRA2ACYP2D6MAPK1ADRB2 | |
| SCHEMBL7354017 | 0.82 | ADRA1A (0.50) | ADRA1AADRA2ACYP2D6MAPK1ADRB2 | |
| SCHEMBL7354012 | 0.82 | ADRA1A (0.50) | ADRA1AADRA2ACYP2D6MAPK1ADRB2 | |
| SCHEMBL28027161 | 0.82 | ADRA1A (0.58) | ADRA1AADRA2ACYP2D6MAPK1ADRB2 | |
| SCHEMBL7061295 | 0.82 | ADRA1A (0.47) | ADRA1AADRA2ACYP2D6MAPK1ADRB2 | |
| SCHEMBL3948168 | 0.81 | ALDH1A1 (0.49) | TSHR | |
| SCHEMBL6372898 | 0.81 | HTT (0.49) | ADRA1AADRA2ACYP2D6MAPK1ADRB2 | |
| SCHEMBL491187 | 0.81 | PTGS2 (0.61) | ADRA1AADRA2ACYP2D6MAPK1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-101163659-B | Antioxidants | MERCK PATENT GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101203278-A | Ultraviolet protection | MERCK PATENT GMBH (DE) | 2008-06-18 | — | — | CN | disclosed |
| CN-101163659-A | Antioxidants | MERCK PATENT GMBH (DE) | 2008-04-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | ADRA1A 1802/4885ADRA2A 2615/4885CYP2D6 252/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | ADRA1A 4075/4885ADRA2A 3707/4885CYP2D6 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.